SOBI Statistics

Total Valuation

Swedish Orphan Biovitrum AB has a market cap or net worth of SEK 103.72 billion. The enterprise value is 121.01 billion.

Market Cap	103.72B
Enterprise Value	121.01B

Important Dates

The last earnings date was Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Swedish Orphan Biovitrum AB has 343.44 million shares outstanding. The number of shares has increased by 11.98% in one year.

Current Share Class	n/a
Shares Outstanding	343.44M
Shares Change (YoY)	+11.98%
Shares Change (QoQ)	+0.61%
Owned by Insiders (%)	0.22%
Owned by Institutions (%)	54.23%
Float	219.73M

Valuation Ratios

The trailing PE ratio is 29.95 and the forward PE ratio is 23.14. Swedish Orphan Biovitrum AB's PEG ratio is 0.75.

PE Ratio	29.95
Forward PE	23.14
PS Ratio	4.09
PB Ratio	2.80
P/TBV Ratio	n/a
P/FCF Ratio	16.32
P/OCF Ratio	n/a
PEG Ratio	0.75

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.60, with an EV/FCF ratio of 19.04.

EV / Earnings	34.44
EV / Sales	4.76
EV / EBITDA	12.60
EV / EBIT	19.97
EV / FCF	19.04

Financial Position

The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.48.

Current Ratio	0.91
Quick Ratio	0.62
Debt / Equity	0.48
Debt / EBITDA	1.86
Debt / FCF	2.81
Interest Coverage	4.44

Financial Efficiency

Return on equity (ROE) is 9.82% and return on invested capital (ROIC) is 6.86%.

Return on Equity (ROE)	9.82%
Return on Assets (ROA)	5.13%
Return on Capital (ROIC)	6.86%
Revenue Per Employee	14.02M
Profits Per Employee	1.94M
Employee Count	1,772
Asset Turnover	0.34
Inventory Turnover	1.37

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +23.64% in the last 52 weeks. The beta is 0.23, so Swedish Orphan Biovitrum AB's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+23.64%
50-Day Moving Average	319.08
200-Day Moving Average	288.16
Relative Strength Index (RSI)	38.41
Average Volume (20 Days)	459,831

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Swedish Orphan Biovitrum AB had revenue of SEK 25.44 billion and earned 3.51 billion in profits. Earnings per share was 10.08.

Revenue	25.44B
Gross Profit	19.99B
Operating Income	6.06B
Pretax Income	4.21B
Net Income	3.51B
EBITDA	9.45B
EBIT	6.06B
Earnings Per Share (EPS)	10.08

Full Income Statement

Balance Sheet

The company has 594.00 million in cash and 17.87 billion in debt, giving a net cash position of -17.27 billion or -50.29 per share.

Cash & Cash Equivalents	594.00M
Total Debt	17.87B
Net Cash	-17.27B
Net Cash Per Share	-50.29
Equity (Book Value)	37.11B
Book Value Per Share	108.01
Working Capital	-1.25B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.66 billion and capital expenditures -309.00 million, giving a free cash flow of 6.35 billion.

Operating Cash Flow	6.66B
Capital Expenditures	-309.00M
Free Cash Flow	6.35B
FCF Per Share	18.50

Full Cash Flow Statement

Margins

Gross margin is 78.60%, with operating and profit margins of 23.83% and 13.82%.

Gross Margin	78.60%
Operating Margin	23.83%
Pretax Margin	16.54%
Profit Margin	13.82%
EBITDA Margin	37.17%
EBIT Margin	23.83%
FCF Margin	24.98%

Dividends & Yields

Swedish Orphan Biovitrum AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.98%
Shareholder Yield	-11.98%
Earnings Yield	3.34%
FCF Yield	6.13%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Swedish Orphan Biovitrum AB has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.58
Piotroski F-Score	n/a